Biosimilars Added To FDA’s Citizen Petition Certification Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency estimates it will receive 26 certifications for citizen petitions that could potentially delay biosimilar or generic applications and one certification for a petition for stay of agency action.
You may also be interested in...
Citizen Petitions Face Strict Certification Requirements Under FDA Final Guidance
FDA will reject petitions that do not include exact language for certification and verification; hedge fund manager files citizen petition opposing approval of Neoprobe's Lymphoseek.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.